TIL therapy or Tumor-infiltrating lymphocyte therapy is an immunotherapy treatment that uses a patient's own immune system by extracting TILs or tumor-infiltrating lymphocytes from a tumour sample. TILs are a type of immune cell called lymphocytes that are found in the tumour microenvironment. TIL therapy helps train a patient's own T cells to recognize and destroy cancer cells. It has shown promising results for treating some types of skin cancer, cervical cancer, lung cancer, breast cancer and others.
The Global TIL Therapy Market is estimated to be valued at USD 0.092 Billion in 2024 and is expected to reach USD 9.20 Billion by 2031, growing at a compound annual growth rate (CAGR) of 39.3% from 2024 to 2031.
Key Takeaways
Key players operating in the global TIL therapy market are Bristol-Myers Squibb, Iovance Biotherapeutics, Neogene Therapeutics,Adaptimmune, Anthropic and others. Iovance Biotherapeutics is a leading player focusing on developing innovative cellular immunotherapies for cancer utilizing peripheral blood lymphocytes.
The company's marketed product is TIL therapy under brand name lifileucel for melanoma. The key opportunities in the Global TIL Therapy Market include utilization of TIL therapy for treating various types of cancers beyond melanoma. Currently, TIL therapy has only been approved for late-stage melanoma treatment but holds promise for different cancer types like lung, breast and others. Various clinical trials are ongoing to evaluate TIL therapy's efficacy for other cancers.
Globally, North America dominates the TIL therapy market owing to regulatory approvals and availability of products. However, Asia Pacific region is anticipated to witness fastest growth owing to rising cancer incidence, availability of low-cost treatment options and growing awareness. Key market players are focusing on geographic expansion plans in emerging regions to tap the growth opportunities.
Market Drivers
Rising global cancer burden is a key driver fueling the adoption of advanced treatment options like TIL therapy. According to WHO, cancer cases are projected to rise by over 60% in the next 20 years. Growing demand for personalized cell therapies with better efficacy and safety profiles compared to traditional treatment is boosting the TIL therapy market.
Market Restrains
High cost of treatment development and product pricing especially for personalized cell therapies like TIL therapy is a major challenge restricting widespread adoption. Limited clinical evidence availability for cancers beyond melanoma is another concern. Longer development timeline and regulatory hurdles also negatively impact the market growth to some extent.
Segment Analysis
The GIL Therapy Market can be segmented based on cancer type into melanoma, lung cancer, breast cancer, and others. Amongst these, the melanoma segment dominates the market currently as it has the strongest clinical evidence and commercial availability for TIL therapy products like Tecartus. Melanoma patients have shown high response rates of over 50% to TIL therapy in various clinical trials conducted so far.
The market can also be segmented based on end-users into cancer treatment centers, hospitals, and research laboratories. Amongst them, cancer treatment centers account for the largest share as most commercially approved TIL therapy like Tecartus are administered to patients in facilities capable of tissue processing and infusing cell therapy products. Hospitals form the second largest segment for TIL therapy market.
Global Analysis
From a regional perspective, North America is expected to continue dominating the global TIL therapy market during the forecast period. High medical expenditure, strong presence of key pharma companies, and faster adoption of novel oncology therapies drive the North American market. Asia Pacific is witnessed to be the fastest growing regional market owing to rising incidence of cancers, increasing healthcare spending, and growing awareness about advanced cell therapies in countries like China, Japan, and South Korea. However, high therapy costs as well as lack of infrastructure for cell processing still restrict the Asia Pacific market to some extent currently. Europe holds the second largest revenue share in the global TIL therapy market supported by favorable reimbursements and widespread availability of approved products in large countries.
Get This Report in Japanese Language: 世界のTIL療法市場
Get This Report in Korean Language: 글로벌 TIL 치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
